U.S. pathway reopens with strict new trial requirements
- The FDA agreed an accelerated approval submission for AMT-130 is reasonable for Q3 2026.
- The agency dropped its sham surgery mandate, asking for a standard-of-care confirmatory trial instead.
- A massive cash balance of $810.3 million extends the operational runway into 2030.
- AMT-260 showed 79 to 100 percent seizure reductions in half of low-dose patients.
- The company expects an FDA Advisory Committee meeting for AMT-130, adding binary regulatory risk.
One asset, two regulators, renewed hope
The story flipped in Q2 2026. After previously demanding a new sham-controlled trial for the Huntington's disease drug AMT-130, the FDA reversed course. It now agrees that submitting a Biologics License Application for accelerated approval using existing data is reasonable.
uniQure expects to file that U.S. application, along with a U.K. equivalent, in Q3 2026. This dual-track filing plan restores the near-term catalyst that investors thought was lost. A massive cash balance of $810.3 million also extended the runway into 2030, giving the company years of flexibility.
The bull case is clear. The U.S. accelerated approval pathway is back open, and the company has the cash to follow it. Furthermore, the pipeline is showing early life, with the AMT-260 epilepsy program demonstrating meaningful seizure reductions in its lowest dose cohort.
The bear case centers on the regulatory finish line. The FDA expects the required standard-of-care confirmatory trial to be well underway by the time of any accelerated approval. The agency also set a high bar by requiring Total Functional Capacity at 36 months as the confirmatory endpoint, and an upcoming Advisory Committee meeting adds significant binary risk.
Royalties fund a trial story
uniQure develops one-time gene therapies for serious rare diseases. These treatments try to fix or change disease biology with a single administration, rather than requiring chronic dosing.
The only approved product tied to uniQure is HEMGENIX for Hemophilia B. CSL Behring commercializes it, and uniQure receives royalties and milestone payments. In early 2026, license revenue made up the entire revenue base.
The company previously subcontracted its manufacturing of HEMGENIX to Genezen. In April 2026, uniQure agreed to terminate this commercial supply agreement, ending its supply obligation once specified batches are delivered. The company relies on outsourced manufacturing for its clinical-stage pipeline.
The core value driver is the clinical and regulatory success of its pipeline. The business relies on a massive cash reserve to fund costly trials until its candidates can be commercialized or licensed.
What uniQure is betting on
AMT-130
The lead program for Huntington's disease. The company plans to submit both a U.S. BLA and a U.K. MAA in Q3 2026.
HEMGENIX
An approved gene therapy for Hemophilia B sold by CSL Behring. It provides royalty revenue but is not the primary driver of the stock.
AMT-260
A clinical candidate for refractory mesial temporal lobe epilepsy. Early data showed meaningful seizure reductions for a subset of low-dose patients.
AMT-191
A clinical candidate for Fabry disease. Dosing in mid- and high-dose cohorts remains paused pending evaluation of dose-limiting toxicities.
Revenue is one stream today
For Q2 2026, uniQure reported revenue primarily from licenses. The company operates as a single business segment focused on gene therapy development.
What could break the story
Confirmatory trial requirements
High impact · High oddsThe FDA agreed a BLA submission is reasonable, but it requires a standard-of-care confirmatory trial to be well underway before potential approval. The FDA wants Total Functional Capacity at 36 months as the primary endpoint, which is a very high bar.
Advisory Committee risk
High impact · Medium oddsManagement expects an FDA Advisory Committee meeting for the AMT-130 application. This public review introduces severe binary risk, as the panel will heavily scrutinize the intermediate endpoints and safety profile.
Pipeline safety setbacks
Medium impact · Medium oddsDosing in the AMT-191 trial for Fabry disease is paused due to dose-limiting toxicities. Early-stage development risk remains high across the broader portfolio.
BLA and MAA review timelines
High impact · Medium oddsSubmissions are planned for Q3 2026, but regulators could refuse to file them or issue a complete response letter. A rejection would severely damage the stock.
In one breath
What is the status of AMT-130?
The FDA agreed that a U.S. Biologics License Application for accelerated approval is reasonable for Q3 2026. The company also plans to file in the U.K. at the same time.
How is uniQure funded?
The company reported $810.3 million in cash and investments at the end of Q2 2026, extending its runway into 2030. The company also earns royalties on HEMGENIX.
What happened to the manufacturing business?
uniQure terminated its commercial supply agreement with Genezen in April 2026. It is moving away from supplying HEMGENIX after final batches are delivered.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 30, 2026
- Score data
- September 6, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near uniQure N.V. in Finn's Biotechnology industry ranking.
